Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Clinical trial NCT06445959 · RECRUITING
Trial details
- NCT number
- NCT06445959
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-29
- Primary completion
- 2027-06-30
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.